KYORIN Pharmaceutical

4569.TPhase 3

Tokyo, JapanFounded 1950kyorin-pharm.co.jp

KYORIN Pharmaceutical is a mid-sized, revenue-generating Japanese pharmaceutical company with a diversified portfolio spanning prescription drugs, over-the-counter (OTC) products, and veterinary medicines. The company leverages its expertise in respiratory and urological diseases to maintain a stable revenue base from commercial products while investing in R&D for future growth. Its strategic focus includes lifecycle management of key brands and advancing its pipeline through internal research and selective partnerships.

Market Cap

$588.9M

Founded

1950

Employees

1000-5000

Focus

Biotech

4569.T · Stock Price

USD 1633.00251.00 (-13.32%)

Historical price data

AI Company Overview

Technology Platform

KYORIN's R&D is disease-area focused, leveraging expertise in molecular targeted drug discovery and formulation technology for respiratory and urological disorders, combined with active lifecycle management of its commercial portfolio.

Pipeline Snapshot

5 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
Imidafenacin + Fesoterodine	Overactive Bladder	Approved
Efzofitimod 3 mg/kg + Efzofitimod 5 mg/kg + Placebo	Pulmonary Sarcoidosis	Phase 3
KRP-104 QD Drug: Placebo Drug: Metformin + Placebo Drug: Metformin + KRP-104 BID...	Type 2 Diabetes	Phase 2
KRP-104 + Placebo	Type 2 Diabetes	Phase 2
KRP-A218 + Placebo + itraconazole	Healthy	Phase 1

Opportunities

Growth opportunities include the successful launch of Fexuprazan in the large Japanese GERD market, geographic expansion of pipeline assets through out-licensing, and capturing market share in the novel chronic cough segment with Gefapixant.

Lifecycle management of mature brands also presents revenue extension opportunities.

Risk Factors

Key risks include patent expiries on core products leading to generic competition, clinical trial failures in the mid-stage pipeline, intense competition in core therapeutic areas from global pharma, and dependency on licensing agreements with partners for significant revenue streams.

Competitive Landscape

KYORIN competes with global pharmaceutical leaders (e.g., GSK, AstraZeneca, Boehringer Ingelheim, Astellas) and domestic Japanese firms (e.g., Takeda) in respiratory, urology, and GI markets. Its differentiation lies in specialized commercial expertise and strong physician relationships in its core Japanese therapeutic areas.

Publications

Patents

Pipeline